Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Current Assets (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Current Assets for 7 consecutive years, with $5.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets fell 21.8% to $5.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.8 million, a 21.8% decrease, with the full-year FY2024 number at $7.5 million, up 203.66% from a year prior.
  • Current Assets was $5.8 million for Q3 2025 at Vivos Therapeutics, down from $6.7 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $39.4 million in Q2 2021 to a low of $2.0 million in Q3 2023.
  • A 5-year average of $12.1 million and a median of $7.5 million in 2024 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: plummeted 80.15% in 2022, then soared 272.75% in 2024.
  • Vivos Therapeutics' Current Assets stood at $27.3 million in 2021, then tumbled by 80.15% to $5.4 million in 2022, then plummeted by 54.63% to $2.5 million in 2023, then soared by 203.66% to $7.5 million in 2024, then decreased by 22.57% to $5.8 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Current Assets are $5.8 million (Q3 2025), $6.7 million (Q2 2025), and $3.6 million (Q1 2025).